SMC accepts restricted use of ranibizumab (Lucentis®) for diabetic macular oedema, following resubmission

Source: Scottish Medicines Consortium (SMC)
Area: Evidence > Drug Specific Reviews
Following a resubmission, the Scottish Medicines Consortium (SMC) has accepted ranibizumab (Lucentis®) for restricted use within NHS Scotland for the treatment of visual impairment due to diabetic macular oedema (DMO) in adults. Its use within this indication is restricted to adults with best corrected visual acuity (BCVA) 75 Early Treatment Diabetic Retinopathy Study (ETDRS) letters or less at baseline.   This advice takes account of the benefits of, and is contingent upon the continuing availability of, a Patient Access (Read more...)

Full Story →